Share

August 2021; 11 (4) Review

Role of Optical Coherence Tomography in Identifying Retinal Biomarkers in Frontotemporal Dementia

A Review

Omar Moinuddin, Nikhila S. Khandwala, Kelly Z. Young, Sanjana K. Sathrasala, Sami J. Barmada, Roger L. Albin, Cagri G. Besirli
First published January 25, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001041
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
174

Share

Article Information

vol. 11 no. 4 e516-e523
DOI: 
https://doi.org/10.1212/CPJ.0000000000001041
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received July 31, 2020
  • Accepted November 12, 2020
  • First Published January 25, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Omar Moinuddin, MD,
    2. Nikhila S. Khandwala, MS,
    3. Kelly Z. Young, BA,
    4. Sanjana K. Sathrasala,
    5. Sami J. Barmada, MD, PhD,
    6. Roger L. Albin, MD and
    7. Cagri G. Besirli, MD, PhD
  1. Omar Moinuddin, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Nikhila S. Khandwala, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Kelly Z. Young, BA,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH: T32-HL125242 (2018-2020) and T32 GM007863 (2015-2018)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. American Heart Association: 20PRE35110083 (2020-now)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sanjana K. Sathrasala,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Sami J. Barmada, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Application in Process Cell line for probing mammalian autophagy, Inventor, Submitted on 03/2018

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 2019-present Live Like Lou Foundation, Scientific Review Board 2020-present Robert Packard Center for ALS Research, Executive Advisory Board, Co-Vice Chair 2020-present Synapticure, Inc., Scientific Review Board 2020-present Symbiosis, Consultant 2020-present Clene Nanomedicine, Consultant

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 5 R01 NS097542-05: RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration NIH-DHHS- US-16-PAF00575 Barmada, Sami J, PI 08/2016-07/2021 1 R01 NS113943-01: Atypical TDP43 isoforms driving neurodegeneration in FTD/ALS NIH-DHHS-US-19-PAF04631 Barmada, Sami J, PI 12/2019-11/2024 5 R01 NS063967-12: Unraveling mechanisms of Niemann-Pick C neuropathology with mouse models NIH-DHHS- US- 16-PAF04766 Co-I with Effort (Principal Investigator: Lieberman, Andrew P) 09/2016-08/2021 5 R01 NS099280-05: Hexanucleotide repeat translation in ALS and Frontotemporal Dementia NIH-DHHS-US- 16- PAF04386 Co-I with Effort (Principal Investigator: Todd, Peter) 09/2016-05/2021 5 P30 AG053760-05: Michigan Alzheimer's Disease Core Center NIH-DHHS-US-15-PAF04931 Co-I with Effort (Principal Investigator: Paulson, Henry L) 08/2016-06/2021 5 R01 NS096785-10: Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration NIH- DHHS-US-15-PAF07535 Co-I with Effort (Principal Investigator: Paulson, Henry) Ivanova, Magdalena 02/2016-01/2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Poly(GR) and poly(GA) as Biomarkers and Therapeutic Targets in C9ORF72-ALS/FTD TargetALS Co-PI (Co-Principal Investigators: Kankel, Mark; Gao, Fen-Biao) 05/2020-05/2022

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Roger L. Albin, MD and
    7. Scientific Advisory Boards:

    1. Biogen: DSMB service for TANGO and COMPASS trials. ICON-Biohaven: DSMB service for M-STAR trial. Vaccinex: DSMB service for Signal-AD trial. Michael J. Fox Foundation: TPPAC membership (therapy development program)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology - Editorial Board,13 years; (2) Movement Disorders - Editorial Board, 6 years.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Takeda - consulting on clinical trial design.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health R25 NS089450 Roger L. Albin, M.D., Principal Investigator University of Michigan Clinical Neuroscientist Training Program (UMCNTP) Project Period: 07/01/19 – 06/30/24 Total Direct Costs: $435,453 Parkinson’s Foundation Research Center of Excellence Roger L. Albin, M.D., Principal Investigator The Thalamus in Parkinson Disease Project Period: 07/01/2019 – 06/30/2023 Total Direct Costs: $2,000,000 National Institutes of Health P50 1P50NS091856-01 Roger L Albin, M.D., Program Director Cholinergic Mechanisms of Gait Dysfunction in Parkinson’s Disease Project Period: 09/30/14 – 06/30/20 Total Direct Costs: $9,603,796 National Institutes of Health R21 NS114749 Roger L. Albin, M.D., Principal Investigator Vigor and the LDR in Parkinson disease Project Period: 12/01/19 - 11/30/21 Total Direct Costs: $390,000 National Institutes of Health P30 1P30AG053760-01 Henry L Paulson, M.D., Ph.D., Program Director Roger Albin, M.D., Core Leader of Research Education Component (RL5) Michigan Alzheimer’s Disease Core Center Project Period: 07/01/16-06/30/21 Total Annual Direct Costs: $1,129,255 National Institutes of Health R01 AG056102 Hiroko Dodge, Ph.D., Principal Investigator Roger L Albin, M.D., Co-Investigator Web-enabled social interaction to delay cognitive decline among seniors with MCI: Phase 1 Project Period: 07/01/17-03/31/22 Total Annual Direct Costs: $236,230 (amount of sub from Oregon Health Sciences University) National Institutes of Health R01 AG051628 Hiroko Dodge, Ph.D., Principal Investigator Benjamin Hampstead, Ph.D., Site Principal Investigator Roger L Albin, M.D., Co-Investigator Conversational engagement as a means to delay Alzheimer’s disease onset: Phase II Project Period: 09/15/16-05/31/21 Total Annual Direct Costs: $132,520 (amount of sub from Oregon Health Sciences University) National Institutes of Health R01 AG058724 Benjamin Hampstead, Ph.D., Principal Investigator Roger L Albin, M.D., Co-Investigator Treating mild cognitive impairment with transcranial direct current stimulation Project Period: 09/01/18-05/31/23 Total Annual Direct Costs: $566,708 National Institutes of Health U24 NS107158 Roger L Albin, M.D. and Kelvin Chou, M.D., Principal Investigators NeuroNEXT Clinical Research Site at the University of Michigan Project Period: 09/01/18-08/31/23 Total Annual Direct Costs: $200,000 Michael J Fox Foundation Yuanfang Guan, Ph.D., Principal Investigator Roger L Albin, M.D., Co-Investigator Accelerometer Data Interpretation of Clinician Input Study by Deep Learning 04/15/2019 - 04/14/2021 Total Annual Direct Costs: $138,218

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Cagri G. Besirli, MD, PhD
    8. Scientific Advisory Boards:

    1. (1) Irenix Medical

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Journal of Ophthalmology, associate editor, 2020

    Patents:

    1. (1) Applicator for Cryo-Anesthesia and Analgesia – Patent number: US10322248, granted 06-18-2019 (2) Applicator for Cryo-Anesthesia and Analgesia – Patent number: US10238814, granted 03-26-2019

    Publishing Royalties:

    1. (1) Up-to-date, topic editor, 2020

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) iRenix Medical (2) CureVac (3) Janssen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH,R01EY029675, PI, 2020 (2)NIH,R01EY020823, co-I, 2020

    Research Support, Academic Entities:

    1. (1) University of Michigan

    Research Support, Foundations and Societies:

    1. (1)The E. Matilda Ziegler Foundation for the Blind (2)International Retinal Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) iRenix Medical

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) ONL-1204/small peptide cell death inhibitor, ONL Therapeutics

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Ophthalmology and Visual Sciences (OM, GGB), W.K. Kellogg Eye Center, University of Michigan; University of Michigan Medical School (NSK, KZY); University of Michigan (SKS); Department of Neurology (SJB, RLA), University of Michigan, Ann Arbor; and GRECC & Neurology Service (RLA), Veterans Affairs Ann Arbor Health System, MI.
  1. Correspondence
    Dr. Besirli cbesirli{at}med.umich.edu

Article usage

Article usage: January 2021 to October 2023

AbstractFullPdfSource
Jan 20218001Highwire
Feb 2021139020Highwire
Mar 202120305Highwire
Apr 202164014Highwire
May 20214108Highwire
Jun 20214505Highwire
Jul 202185015Highwire
Aug 20211111216Highwire
Sep 202120078Highwire
Oct 202111344Highwire
Nov 2021115311Highwire
Dec 202111689Highwire
Jan 202219026Highwire
Feb 202213247Highwire
Mar 20225256Highwire
Apr 20228612Highwire
May 20226223Highwire
Jun 20226312Highwire
Jul 20224145Highwire
Aug 20225124Highwire
Sep 20226635Highwire
Oct 20227616Highwire
Nov 20228631Highwire
Dec 20224311Highwire
Jan 20236703Highwire
Feb 20234400Highwire
Mar 20236703Highwire
Apr 20231700Highwire
May 20237511Highwire
Jun 20232800Highwire
Jul 20235910Highwire
Aug 20233623Highwire
Sep 2023400Highwire
Oct 20235200Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles